Literature DB >> 23219016

Opioid receptors: distinct roles in mood disorders.

Pierre-Eric Lutz1, Brigitte L Kieffer.   

Abstract

The roles of opioid receptors in pain and addiction have been extensively studied, but their function in mood disorders has received less attention. Accumulating evidence from animal research reveals that mu, delta and kappa opioid receptors (MORs, DORs and KORs, respectively) exert highly distinct controls over mood-related processes. DOR agonists and KOR antagonists have promising antidepressant potential, whereas the risk-benefit ratio of currently available MOR agonists as antidepressants remains difficult to evaluate, in addition to their inherent abuse liability. To date, both human and animal studies have mainly examined MORs in the etiology of depressive disorders, and future studies will address DOR and KOR function in established and emerging neurobiological aspects of depression, including neurogenesis, neurodevelopment, and social behaviors.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23219016      PMCID: PMC3594542          DOI: 10.1016/j.tins.2012.11.002

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  153 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

2.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

3.  The involvement of glial cells in the development of morphine tolerance.

Authors:  P Song; Z Q Zhao
Journal:  Neurosci Res       Date:  2001-03       Impact factor: 3.304

4.  Decreased response to social defeat stress in μ-opioid-receptor knockout mice.

Authors:  Hiroshi Komatsu; Arihisa Ohara; Kazumasu Sasaki; Hiromi Abe; Hisaki Hattori; F Scott Hall; George R Uhl; Ichiro Sora
Journal:  Pharmacol Biochem Behav       Date:  2011-06-15       Impact factor: 3.533

5.  Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles.

Authors:  A L Svingos; C Chavkin; E E Colago; V M Pickel
Journal:  Synapse       Date:  2001-12-01       Impact factor: 2.562

6.  Effects of morphine, naloxone and their interaction in the learned-helplessness paradigm in rats.

Authors:  A Besson; A M Privat; A Eschalier; J Fialip
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

Review 7.  Neurodevelopmental origins of depressive disorders.

Authors:  Mark S Ansorge; René Hen; Jay A Gingrich
Journal:  Curr Opin Pharmacol       Date:  2006-12-21       Impact factor: 5.547

8.  The antidepressant-like effect of human opiorphin via opioid-dependent pathways in mice.

Authors:  Qing-Zhen Yang; Song-Song Lu; Xiao-Zhu Tian; Ai-Min Yang; Wan-Wen Ge; Qiang Chen
Journal:  Neurosci Lett       Date:  2010-12-09       Impact factor: 3.046

9.  Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women.

Authors:  Susan E Kennedy; Robert A Koeppe; Elizabeth A Young; Jon-Kar Zubieta
Journal:  Arch Gen Psychiatry       Date:  2006-11

10.  NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action.

Authors:  Pattipati S Naidu; Aron H Lichtman; Carey C Archer; Everett L May; Louis S Harris; Mario D Aceto
Journal:  Eur J Pharmacol       Date:  2007-03-30       Impact factor: 4.432

View more
  168 in total

Review 1.  Non-nociceptive roles of opioids in the CNS: opioids' effects on neurogenesis, learning, memory and affect.

Authors:  Cherkaouia Kibaly; Chi Xu; Catherine M Cahill; Christopher J Evans; Ping-Yee Law
Journal:  Nat Rev Neurosci       Date:  2019-01       Impact factor: 34.870

Review 2.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

3.  An extract of Synedrella nodiflora (L) Gaertn exhibits antidepressant properties through monoaminergic mechanisms.

Authors:  Patrick Amoateng; Kennedy Kwami Edem Kukuia; Jeffrey Amoako Mensah; Dorcas Osei-Safo; Samuel Adjei; Audrey Akyea Eklemet; Emmanuel Atsu Vinyo; Thomas K Karikari
Journal:  Metab Brain Dis       Date:  2018-05-12       Impact factor: 3.584

Review 4.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

Review 5.  The multiple facets of opioid receptor function: implications for addiction.

Authors:  Pierre-Eric Lutz; Brigitte L Kieffer
Journal:  Curr Opin Neurobiol       Date:  2013-02-28       Impact factor: 6.627

6.  Pharmacological Properties of δ-Opioid Receptor-Mediated Behaviors: Agonist Efficacy and Receptor Reserve.

Authors:  Isaac J Dripps; Ruizhuo Chen; Amanda M Shafer; Kathryn E Livingston; Alexander Disney; Stephen M Husbands; John R Traynor; Kenner C Rice; Emily M Jutkiewicz
Journal:  J Pharmacol Exp Ther       Date:  2020-05-28       Impact factor: 4.030

7.  A cell-based, high-throughput homogeneous time-resolved fluorescence assay for the screening of potential κ-opioid receptor agonists.

Authors:  Yue Wang; Ming Yan; Guang-Yao Zheng; Ling He; Huan Yang
Journal:  Acta Pharmacol Sin       Date:  2014-06-16       Impact factor: 6.150

8.  Long-lasting effects of adolescent oxycodone exposure on reward-related behavior and gene expression in mice.

Authors:  Victoria Sanchez; Marco D Carpenter; Nicole L Yohn; Julie A Blendy
Journal:  Psychopharmacology (Berl)       Date:  2016-09-13       Impact factor: 4.530

9.  The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors.

Authors:  Isaac J Dripps; Qin Wang; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz
Journal:  Psychopharmacology (Berl)       Date:  2016-09-13       Impact factor: 4.530

Review 10.  Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.

Authors:  N T Burford; J R Traynor; A Alt
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.